JP2022543742A5 - - Google Patents
Info
- Publication number
- JP2022543742A5 JP2022543742A5 JP2022503794A JP2022503794A JP2022543742A5 JP 2022543742 A5 JP2022543742 A5 JP 2022543742A5 JP 2022503794 A JP2022503794 A JP 2022503794A JP 2022503794 A JP2022503794 A JP 2022503794A JP 2022543742 A5 JP2022543742 A5 JP 2022543742A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- item
- antigen
- promoter
- fusion polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024198293A JP2025015619A (ja) | 2019-07-19 | 2024-11-13 | 免疫療法のための融合ポリペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876338P | 2019-07-19 | 2019-07-19 | |
| US62/876,338 | 2019-07-19 | ||
| PCT/US2020/042753 WO2021016174A1 (en) | 2019-07-19 | 2020-07-20 | Fusion polypeptide for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024198293A Division JP2025015619A (ja) | 2019-07-19 | 2024-11-13 | 免疫療法のための融合ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543742A JP2022543742A (ja) | 2022-10-14 |
| JP2022543742A5 true JP2022543742A5 (cg-RX-API-DMAC7.html) | 2023-07-28 |
| JP7676358B2 JP7676358B2 (ja) | 2025-05-14 |
Family
ID=74192452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503794A Active JP7676358B2 (ja) | 2019-07-19 | 2020-07-20 | 免疫療法のための融合ポリペプチド |
| JP2024198293A Pending JP2025015619A (ja) | 2019-07-19 | 2024-11-13 | 免疫療法のための融合ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024198293A Pending JP2025015619A (ja) | 2019-07-19 | 2024-11-13 | 免疫療法のための融合ポリペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220133802A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3999079A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7676358B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220035471A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115298208A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020315796A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022000976A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3148072A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289887A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022000769A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021016174A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240076351A1 (en) * | 2021-01-15 | 2024-03-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Hybrid and truncated immune cell proteins |
| EP4305174A4 (en) * | 2021-03-10 | 2025-04-30 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES TO DETERMINE THE PRESENCE AND/OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES |
| US12486310B2 (en) | 2021-04-21 | 2025-12-02 | Brigham Young University | Metastasis inhibiting protein |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| WO2023020471A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd123-targetting antibodies and uses thereof in cancer therapies |
| WO2023081542A1 (en) * | 2021-11-02 | 2023-05-11 | Christopher Mendoza | Metastasis inhibiting protein |
| JP2025501272A (ja) | 2021-12-28 | 2025-01-17 | ムネモ・セラピューティクス | 不活性化されたsuv39h1及び改変tcrを有する免疫細胞 |
| AU2023209589A1 (en) | 2022-01-21 | 2024-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Modulation of suv39h1 expression by rnas |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| WO2024086842A2 (en) * | 2022-10-21 | 2024-04-25 | Memorial Sloan-Kettering Cancer Center | Cells and compositions for treating cancer |
| JP2025536892A (ja) * | 2022-10-21 | 2025-11-12 | メモリアル スローン ケタリング キャンサー センター | 抗cd70キメラ受容体を発現する細胞及びその用途 |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向psma及ca9之系統 |
| EP4680748A1 (en) | 2023-03-13 | 2026-01-21 | Arsenal Biosciences, Inc. | Synthetic pathway activators |
| WO2024227145A1 (en) * | 2023-04-27 | 2024-10-31 | Memorial Sloan-Kettering Cancer Center | Enhanced fusion polypeptide for immunotherapy |
| WO2026078056A1 (en) * | 2024-10-09 | 2026-04-16 | Leibniz-Institut Für Immuntherapie (Lit) | Engineered tnfr ligands |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2002221780A1 (en) * | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| EP3770168A1 (en) * | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| PT3310805T (pt) * | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| CN106929523A (zh) * | 2015-12-29 | 2017-07-07 | 中国人民解放军第二军医大学 | 酵母表达重组hCD80-GPI融合蛋白的制备及其在抗肿瘤中的应用 |
| US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
| US11365237B2 (en) | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| EP3231813A1 (en) * | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
| KR102614675B1 (ko) | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| AU2017248830B2 (en) * | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| SG11201808457PA (en) * | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| JP7467117B2 (ja) * | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
| US11725210B2 (en) | 2017-03-17 | 2023-08-15 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| CN108866003A (zh) * | 2017-05-16 | 2018-11-23 | 科济生物医药(上海)有限公司 | 基因工程化的细胞及应用 |
| CN118853581A (zh) * | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| WO2019084234A1 (en) * | 2017-10-26 | 2019-05-02 | St. Jude Childen's Research Hospital, Inc. | METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS |
| IL326873A (en) * | 2017-12-29 | 2026-04-01 | Memorial Sloan Kettering Cancer Center | Enhanced chimeric antigen receptors and uses thereof |
-
2020
- 2020-07-20 EP EP20843016.5A patent/EP3999079A4/en active Pending
- 2020-07-20 CA CA3148072A patent/CA3148072A1/en active Pending
- 2020-07-20 MX MX2022000769A patent/MX2022000769A/es unknown
- 2020-07-20 WO PCT/US2020/042753 patent/WO2021016174A1/en not_active Ceased
- 2020-07-20 KR KR1020227005411A patent/KR20220035471A/ko not_active Withdrawn
- 2020-07-20 AU AU2020315796A patent/AU2020315796A1/en active Pending
- 2020-07-20 CN CN202080063644.9A patent/CN115298208A/zh active Pending
- 2020-07-20 JP JP2022503794A patent/JP7676358B2/ja active Active
- 2020-07-20 BR BR112022000976A patent/BR112022000976A2/pt unknown
-
2022
- 2022-01-16 IL IL289887A patent/IL289887A/en unknown
- 2022-01-19 US US17/578,989 patent/US20220133802A1/en active Pending
-
2024
- 2024-11-13 JP JP2024198293A patent/JP2025015619A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230071733A1 (en) | Immunoconjugates | |
| CA2791383C (en) | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins | |
| RU2761377C2 (ru) | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 | |
| JP2020525536A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537925A5 (cg-RX-API-DMAC7.html) | ||
| JP2025517479A (ja) | Bcma-cd19を標的とする二重特異性キメラ抗原受容体およびその用途 | |
| AU2021383237A1 (en) | Nkg2a-targeting antibody and use thereof | |
| JP2024525492A5 (cg-RX-API-DMAC7.html) | ||
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体(ai-car)及びそれを発現する細胞 | |
| AU2024244733B2 (en) | Bispecific chimeric antigen receptors targeting cd20 and bcma | |
| JP2022513372A5 (cg-RX-API-DMAC7.html) | ||
| JP2024514974A5 (cg-RX-API-DMAC7.html) | ||
| WO2020087116A1 (en) | Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof | |
| JP2026513997A (ja) | Bcma及びcd19を標的とする二重特異性キメラ抗原受容体 | |
| JP2022548112A5 (cg-RX-API-DMAC7.html) | ||
| CN120476143A (zh) | 包含与il18组合的新型cd19结合剂的car-t构建体及其使用方法 | |
| CN115873802A (zh) | 嵌合抗原受体免疫细胞及其制法和应用 | |
| RU2022103913A (ru) | Слитый полипептид для иммунотерапии | |
| KR20190028343A (ko) | 뉴로필린 1 (Neuropilin 1, NRP1)에 특이적으로 결합하는 펩타이드를 포함하는 조절 T 세포의 활성을 억제하기 위한 조성물 | |
| EP4566619A1 (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| HK40125822A (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| AU2023289687A1 (en) | Targeting modules against cd123 for use in a method for stimulating a chimeric antigen receptor-mediated immune response in a mammal | |
| WO2025081163A1 (en) | Compositions for the treatment of cancer |